NCT05431270: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Sponsor: Phanes Therapeutics. Phase: PHASE1. Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma